ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In the ENESTnd study, a trial comparing imatinib versus nilotinib as first-line treatment for CML, shows that the use of more potent TKIs as those of second generation can indeed greatly increase the percentage of the patients who at 3 months achieve a value of BCR-ABL trascripts below the 10 %IS in the high and intermediate Sokal’s risk groups: the percentage of the high-risk group patients achieving a value of BCR-ABLIS <10 % when treated with nilotinib (85 %) is almost double with respect to what is observed in the group treated with imatinib (43 %) [33].